The estimated Net Worth of Laura Francis is at least $11.6 Million dollars as of 16 August 2024. Ms Francis owns over 9,967 units of SI-BONE Inc stock worth over $7,433,279 and over the last 21 years she sold SIBN stock worth over $3,506,072. In addition, she makes $617,854 as CEO & Director at SI-BONE Inc.
Ms has made over 41 trades of the SI-BONE Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 9,967 units of SIBN stock worth $137,943 on 16 August 2024.
The largest trade she's ever made was exercising 68,669 units of SI-BONE Inc stock on 14 June 2024 worth over $300,770. On average, Ms trades about 6,100 units every 33 days since 2003. As of 16 August 2024 she still owns at least 492,923 units of SI-BONE Inc stock.
You can see the complete history of Ms Francis stock trades at the bottom of the page.
Laura A. Francis is the CEO & Director at SI-BONE Inc.
As the CEO & Director of SI-BONE Inc, the total compensation of Ms Francis at SI-BONE Inc is $617,854. There are 7 executives at SI-BONE Inc getting paid more, with Aleksey Miller having the highest compensation of $59,963,000.
Ms Francis is 54, she's been the CEO & Director of SI-BONE Inc since . There are 12 older and 19 younger executives at SI-BONE Inc. The oldest executive at SI-BONE Inc is Valery Serdyukov, 74, who is the Non-Executive Director.
Laura's mailing address filed with the SEC is C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA, CA, 95050.
Over the last 6 years, insiders at SI-BONE Inc have traded over $114,943,926 worth of SI-BONE Inc stock and bought 1,250,000 units worth $18,750,000 . The most active insiders traders include David P Bonita, Advisors Llc Orbi Med Capit..., and John Gordon Freund. On average, SI-BONE Inc executives and independent directors trade stock every 8 days with the average trade being worth of $401,535. The most recent stock trade was executed by Anshul Maheshwari on 3 September 2024, trading 1,414 units of SIBN stock currently worth $23,119.
si-bone® is focused on helping patients in one of the most under-served, under-diagnosed, and under-treated areas in orthopedics, the sacroiliac (si) joint. si-bone developed an innovative, patented implant to fuse the si joint. the ifuse implant system® provides a less invasive alternative to traditional sacroiliac (si) joint fusion surgery and has been used in over 25,000 procedures to date. the company is managed by an experienced team of executives from kyphon, medtronic, inbone, saint francis and several start up orthopedic and spine companies. the ifuse implant system is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. this includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. there are potential risks associated with the ifuse implant system. it may not be appropriate for al
SI-BONE Inc executives and other stock owners filed with the SEC include: